RXi Pharmaceuticals this week announced that the US Food and Drug Administration has approved the company's investigational new drug application to begin human testing of an RNAi-based drug for scar reduction.

The drug, called RXI-109, uses RXi's so-called self-delivering RNAi technology to inhibit connective tissue growth factor, a protein linked to wound healing and other fibrotic processes. It will be tested in a phase I trial in surgical patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec
04
Sponsored by
Sophia Genetics

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.